<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069950</url>
  </required_header>
  <id_info>
    <org_study_id>16-1341</org_study_id>
    <nct_id>NCT03069950</nct_id>
  </id_info>
  <brief_title>Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver</brief_title>
  <official_title>A Randomized, Multicenter Phase II Study of Panitumumab Plus FOLFIRI With or Without Hepatic Arterial Infusion as Second-Line Treatment in Patients With Wild Type RAS Who Have Unresectable Hepatic Metastases From Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queens Cancer Center of Queens Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if patients treated with both regional chemotherapy using&#xD;
      the HAI pump and intravenous chemotherapy are able to have their liver tumors removed&#xD;
      surgically (resected), versus treatment with only intravenous chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of accrual&#xD;
  </why_stopped>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Actual">May 16, 2019</completion_date>
  <primary_completion_date type="Actual">May 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resection rate assessed using RECIST (version 1.1)</measure>
    <time_frame>3 months</time_frame>
    <description>Treatment evaluation will be done using RECIST (version 1.1) The patient will be assessed with repeat CT scans as specified. If at any time after 3 cycles (or 3 months) the patient is able to undergo a complete resection of all hepatic metastases they will proceed to operative assessment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Adenocarcinoma Metastatic to the Liver</condition>
  <arm_group>
    <arm_group_label>HAI FUDR/Dex in addition to Pmab plus FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab plus FOLFIRI on Day 1 and Day 15 of each cycle. HAI pump therapy with FUDR and Dex on Day 1 of each cycle. Patients will start protocol therapy approximately 2 weeks after surgery. All patients will receive Panitumumab (6 mg/kg IV over 60 min). The HAI FUDR group will receive FOLFIRI in the following dosing; 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pmab plus FOLFIRI alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dosing of FOLFIRI in the systemic arm will be 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), bolus 5FU 400mg/ m2 and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine (FUDR)</intervention_name>
    <description>5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)</description>
    <arm_group_label>HAI FUDR/Dex in addition to Pmab plus FOLFIRI</arm_group_label>
    <arm_group_label>Pmab plus FOLFIRI alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan (CPT-11)</intervention_name>
    <description>Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.</description>
    <arm_group_label>HAI FUDR/Dex in addition to Pmab plus FOLFIRI</arm_group_label>
    <arm_group_label>Pmab plus FOLFIRI alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLUOROURACIL</intervention_name>
    <description>5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)</description>
    <arm_group_label>HAI FUDR/Dex in addition to Pmab plus FOLFIRI</arm_group_label>
    <arm_group_label>Pmab plus FOLFIRI alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PANITUMUMAB</intervention_name>
    <description>Panitumumab (6 mg/kg IV over 60 min)</description>
    <arm_group_label>HAI FUDR/Dex in addition to Pmab plus FOLFIRI</arm_group_label>
    <arm_group_label>Pmab plus FOLFIRI alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DEXAMETHASONE</intervention_name>
    <description>flat dose of 25 mg on Day 1</description>
    <arm_group_label>HAI FUDR/Dex in addition to Pmab plus FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)</description>
    <arm_group_label>HAI FUDR/Dex in addition to Pmab plus FOLFIRI</arm_group_label>
    <arm_group_label>Pmab plus FOLFIRI alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of histologically confirmed colorectal adenocarcinoma metastatic to the liver&#xD;
             with no clinical or radiographic evidence of extrahepatic disease. Confirmation of&#xD;
             diagnosis must be performed by the enrolling institution.&#xD;
&#xD;
          -  Patients must have a primary L sided colorectal cancer, (at or distal to the splenic&#xD;
             flexure)&#xD;
&#xD;
          -  Confirmed RAS/RAF wild type tumor. Paraffin-embedded tumor tissue obtained from the&#xD;
             primary tumor or metastasis&#xD;
&#xD;
          -  Have received prior treatment for metastatic disease with oxaliplatin-based regimen&#xD;
             and either&#xD;
&#xD;
               -  Had disease progression OR&#xD;
&#xD;
               -  Had stable disease OR&#xD;
&#xD;
               -  Discontinued oxaliplatin due to neuropathy&#xD;
&#xD;
          -  Patients must meet the following criteria for unresectability as determined by two&#xD;
             hepatobiliary surgeons and one radiologist:&#xD;
&#xD;
               -  When a margin negative resection would require resection of all three hepatic&#xD;
                  veins, both portal veins, or the retrohepatic vena cava.&#xD;
&#xD;
               -  Requiring a resection that leaves less than 2 hepatic segments (not including the&#xD;
                  caudate lobe) behind with adequate arterial/portal inflow, venous outflow and&#xD;
                  biliary drainage. **&#xD;
&#xD;
                  **A patient is considered resectable if the procedure includes a minor wedge or&#xD;
                  thermo-ablation encompassing 10% or less of the volume of the remaining 2&#xD;
                  segments.&#xD;
&#xD;
               -  Patient&quot;s liver metastases must comprise &lt;70% of the liver parenchyma. All&#xD;
                  patients must be clinically fit to undergo surgery as determined by the&#xD;
                  pre-operative evaluation&#xD;
&#xD;
          -  Lab values within 14 days prior to enrollment/randomization:&#xD;
&#xD;
               -  WBC ≥ 3.0 K/uL&#xD;
&#xD;
               -  ANC &gt; 1.5 K/uL&#xD;
&#xD;
               -  Platelets ≥ 100,000/uL&#xD;
&#xD;
          -  Renal function (≤ 10 days prior to enrollment/randomization) °Creatinine ≤ 1.5 mg/dL&#xD;
             or creatinine clearance ≥ 50 mL/min calculated by the Cockcroft-Gault method as&#xD;
             follows:&#xD;
&#xD;
        Cockcroft-Gault method as follows:&#xD;
&#xD;
          -  Male creatinine clearance = (140 -age in years) x (weight in Kg) / (serum Cr in mg/dl&#xD;
             x 72)&#xD;
&#xD;
          -  Female creatinine clearance = (140 - age in years) x (weight in Kg) x 0.85 / (serum Cr&#xD;
             in mg/dl x 72) (use of creatinine clearance per protocol based on chemotherapy&#xD;
             regimen)&#xD;
&#xD;
               -  Hepatic function, as follows: (≤ 10 days prior to enrollment/randomization)&#xD;
&#xD;
          -  Total Bilirubin ≤ 1.5 mg/dl&#xD;
&#xD;
               -  Calcium ≥ lower limit of normal (≤ 48 hours prior to enrollment/randomization)&#xD;
&#xD;
               -  KPS ≥ 60% (ECOG (or Karnofsky) performance status (preferably 0 or 1/≥ 60% for&#xD;
                  Karnofsky))&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt; 18 years of age&#xD;
&#xD;
          -  Patients who have received more than one chemotherapy regimen for metastatic disease&#xD;
&#xD;
          -  Patients who are chemotherapy naïve&#xD;
&#xD;
          -  Prior radiation to the liver (Prior radiation therapy to the pelvis is acceptable if&#xD;
             completed at least 4 weeks prior to registration)&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
             °Active infection includes patients with positive blood cultures&#xD;
&#xD;
          -  Prior treatment with HAI FUDR&#xD;
&#xD;
          -  Prior TACE&#xD;
&#xD;
          -  Female patients who are pregnant or lactating - or planning to become pregnant within&#xD;
             6 months after the end of the treatment (female patients of child-bearing potential&#xD;
             must have negative pregnancy test ≤ 72 hours before enrollment and randomization, and&#xD;
             must have a negative pregnancy test ≤ 72 hours prior to treatment start)&#xD;
&#xD;
          -  If a patient has any serious medical problems which may preclude receiving this type&#xD;
             of treatment&#xD;
&#xD;
          -  Patients with history or known presence of primary CNS tumors, seizures not&#xD;
             well-controlled with standard medical therapy, or history of stroke will also be&#xD;
             excluded.&#xD;
&#xD;
          -  Serious or non-healing active wound, ulcer, or bone fracture&#xD;
&#xD;
          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan&#xD;
&#xD;
          -  Patients who have a diagnosis of Gilbert&quot;s disease&#xD;
&#xD;
          -  History of other malignancy, except:&#xD;
&#xD;
               1. Malignancy treated with curative intent and with no known active disease present&#xD;
                  for ≥ 3 years prior to randomization and felt to be at low risk for recurrence by&#xD;
                  the treating physician&#xD;
&#xD;
               2. Adequately treated non-melanomatous skin cancer or lentigo maligna without&#xD;
                  evidence of disease&#xD;
&#xD;
               3. Adequately treated cervical carcinoma in situ without evidence of disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Cercek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Arterial Infusion</keyword>
  <keyword>Floxuridine (FUDR)</keyword>
  <keyword>Irinotecan (CPT-11)</keyword>
  <keyword>FLUOROURACIL</keyword>
  <keyword>PANITUMUMAB</keyword>
  <keyword>16-1341</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

